Teenretrovirale middel: Verskil tussen weergawes
Content deleted Content added
k Robot: standardiseer verwysingsjablone en voeg argiefskakels in. |
k Robot: standardiseer verwysingsjablone en voeg argiefskakels in. |
||
Lyn 33:
In Augustus 2019 is die verkose eerste- en tweedelinie terapie in die [[VSA]] en Suid-Afrika:
* [[Tenofovir]], [[lamivudien]] en [[dolutegravir]].<ref>{{cite web |url=https://www.who.int/news-room/detail/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations |title=WHO recommends dolutegravir as preferred HIV treatment option in all populations |website=www.who.int |date=22 Julie 2019 |access-date=13 Februarie 2020 |language=en |archive-url=https://web.archive.org/web/20200526204908/https://www.who.int/news-room/detail/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations |archive-date=26 Mei 2020 |url-status=live |df=dmy-all}}</ref> Lg. vervang [[efavirens]] in die trippelkombinasieterapie.
==Verwysings==
| |||